Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 3332 | 29.51 |
09:36 ET | 200 | 29.39 |
09:41 ET | 9158 | 29.13 |
09:43 ET | 200 | 29.17 |
09:45 ET | 8483 | 29.275 |
09:48 ET | 100 | 29.19 |
09:50 ET | 576 | 29.19 |
09:52 ET | 567 | 29.17 |
09:54 ET | 500 | 29.035 |
09:56 ET | 1899 | 29.1 |
09:57 ET | 550 | 29.24 |
09:59 ET | 400 | 29.34 |
10:01 ET | 700 | 29.395 |
10:03 ET | 50689 | 29.7899 |
10:06 ET | 1885 | 29.5 |
10:08 ET | 137 | 29.42 |
10:10 ET | 1439 | 29.5 |
10:12 ET | 789 | 29.48 |
10:14 ET | 3517 | 29.65 |
10:15 ET | 1210 | 29.585 |
10:17 ET | 820 | 29.59 |
10:19 ET | 29767 | 29.63 |
10:21 ET | 3100 | 29.685 |
10:24 ET | 1019 | 29.715 |
10:26 ET | 902 | 29.71 |
10:28 ET | 1600 | 29.66 |
10:30 ET | 1100 | 29.85 |
10:32 ET | 4005 | 29.82 |
10:33 ET | 4309 | 29.82 |
10:35 ET | 2030 | 29.9 |
10:37 ET | 2100 | 29.88 |
10:39 ET | 33712 | 29.9925 |
10:42 ET | 1230 | 29.985 |
10:44 ET | 332 | 29.9 |
10:46 ET | 704 | 29.82 |
10:48 ET | 620 | 29.74 |
10:50 ET | 100 | 29.765 |
10:51 ET | 200 | 29.735 |
10:53 ET | 968 | 29.61 |
10:55 ET | 500 | 29.545 |
10:57 ET | 900 | 29.545 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 4.2B | -15.4x | --- |
Crinetics Pharmaceuticals Inc | 4.2B | -14.6x | --- |
Biohaven Ltd | 3.7B | -4.5x | --- |
BridgeBio Pharma Inc | 4.9B | -10.2x | --- |
Dyne Therapeutics Inc | 3.4B | -10.0x | --- |
Madrigal Pharmaceuticals Inc | 5.1B | -9.5x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-1.92 |
Book Value | $4.24 |
P/E Ratio | -15.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.